

Special Issue

Nanomedicine in Cancer: Therapy and Drug Discovery

Message from the Guest Editor

It is well known that cancer remains one of the deadliest diseases worldwide. Nanomedicine and nanomaterials have developed rapidly in recent years and are used in various fields of biomedicine. Nanomedicine is changing the way in which cancer is treated. Research shows that nanoparticles have the potential to modulate cancer cells and help to improve the efficacy of anti-cancer chemotherapy and immunotherapy. Nanomaterials also play an important role in the development and delivery of anti-cancer drugs. This Special Issue, "Nanomedicine in Cancer: Therapy and Drug Discovery", is led by *Biomedicines*. Our topics mainly cover the following: research and development of new nano anti-cancer drugs, exploration of therapeutic targets for various types of cancer, the application of nano drugs in cancer treatment delivery and new applications of nanomedicine in cancer therapy, etc. We welcome scholars in the field to submit their latest results, including original papers and reviews.

Guest Editor

Dr. Rizwan Wahab

Zoology Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/147979

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).